The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $3.33

Today's change+0.13 +4.06%
Updated May 25 4:00 PM EDT. Delayed by at least 15 minutes.
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $3.33

Today's change+0.13 +4.06%
Updated May 25 4:00 PM EDT. Delayed by at least 15 minutes.

PDL BioPharma Inc crosses above 125-day moving average

PDL BioPharma Inc closed up sharply Wednesday, rallying (U.S.)$0.13 or 4.06% to (U.S.)$3.33 and crossing above its 125-day moving average. Over the last five days, shares have gained 6.05%, but are down 5.93% for the last year to date. Shares have underperformed the S&P 500 by 48.33% during the last year.

Key company metrics

  • Open(U.S.) $3.25
  • Previous close(U.S.) $3.20
  • High(U.S.) $3.35
  • Low(U.S.) $3.23
  • Bid / Ask(U.S.) $3.14 / (U.S.) $3.45
  • YTD % change-5.93%
  • Volume1,211,582
  • Average volume (10-day)1,080,328
  • Average volume (1-month)1,402,559
  • Average volume (3-month)2,135,165
  • 52-week range(U.S.) $2.58 to (U.S.) $6.83
  • Beta0.71
  • Trailing P/E1.80×
  • P/E 1 year forward7.11×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $0.20
  • Dividend yield6.01%
  • Trailing EPS(U.S.) $1.85
Updated May 25 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.72%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue103178125138
Total other revenue--------
Total revenue103178125138
Gross profit--------
Total cost of revenue--------
Total operating expense101087
Selling / general / administrative101387
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)---200
Other operating expenses, total--------
Operating income93168116131
Interest income (expense), net non-operating-5-5-6-7
Gain (loss) on sale of assets--------
Other--------
Income before tax89163110124
Income after tax561016978
Income tax, total33624145
Net income561016978
Total adjustments to net income--------
Net income before extra. items561016978
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items561016978
Inc. avail. to common incl. extra. items561016978
Diluted net income561016978
Dilution adjustment--------
Diluted weighted average shares164165164165
Diluted EPS excluding extraordinary itemsvalue per share0.340.610.420.47
Dividends per sharevalue per share0.050.150.150.15
Diluted normalized EPSvalue per share0.340.600.420.47